Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
STING is a critical adaptor protein in the innate immune system that acts as a cytosolic DNA sensor and triggers type I interferon production. Upon detection of cytosolic DNA or binding of cyclic dinucleotides (CDNs), STING undergoes conformational changes, translocates to perinuclear compartments, recruits TBK1 kinase, and activates IRF3, leading to the expression of interferon-stimulated genes. STING plays a role in antiviral defense, cancer immunity, and inflammatory responses, making it a therapeutic target for infectious diseases, cancer immunotherapy, and inflammatory disorders. Pharmacological modulation of STING, using both agonists and inhibitors, is under investigation for clinical use.
Agonists: Activation of STING leading to interferon production and immune stimulation. Inhibitors: Blockade of STING activation, dampening interferon production and inflammatory response.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Stimulator of interferon genes protein (STING).